AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17217436 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 47
Study 17217436 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV23
Number of subjects: 47
Study 15889026 — intervention group
Group type: EXPERIMENTAL
Intervention: Handyscale (digital dynamometer)
Number of subjects: 30
Study 15889026 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized strength test in the Constant‐Murley shoulder assessment
Number of subjects: 30
Study 12572527 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusafungine nasal spray
Number of subjects: 20
Study 12572527 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 20
Study 9459381 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g psyllium three times daily
Number of subjects: 8
Study 7619678 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day-1)
Number of subjects: 36
Study 7619678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg day-1)
Number of subjects: 36
Study 7619678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2474474 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial fiber
Number of subjects: 40
Study 2474474 — intervention group
Group type: COMPARATOR
Intervention: Naked fiber
Number of subjects: 40
Study 6117392 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 5
Study 6117392 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 5
Study 6117392 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 5
Study 31217962 — intervention group
Group type: EXPERIMENTAL
Intervention: MFI-led Community Health Worker program
Number of subjects: 70
Study 31217962 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 27136960 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose polyethylene glycol (PEG)
Number of subjects: 105
Study 26281972 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAR + metformin
Number of subjects: 337
Study 26281972 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAR + sulfonylurea
Number of subjects: 337
Study 26281972 — intervention group
Group type: COMPARATOR
Intervention: 3OAD (metformin or glyburide)
Number of subjects: 337
Study 26281972 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAR (substituted for TZD)
Number of subjects: 337
Study 24411512 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal curriculum on caring for people with disabilities
Number of subjects: 0
Study 24411512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific disabilities curriculum)
Number of subjects: 0
Study 22070720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 22070720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20190646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 0
Study 20190646 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 18612703 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative combined modality adjuvant therapy (chemotherapy, chemoradiation, or both); specific dosages and durations not mentioned.
Number of subjects: 0
Study 18612703 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy; specific type not mentioned.
Number of subjects: 0
Study 15773068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 19
Study 15773068 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 19
Study 15773068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 19
Study 15773068 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical grade placebo
Number of subjects: 19
Study 12454574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein formula
Number of subjects: 10
Study 12454574 — intervention group
Group type: COMPARATOR
Intervention: Nonhydrolyzed protein formula
Number of subjects: 10
Study 10086330 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily doses of 9 or 12 x 10(6) IL‐2 units/m2
Number of subjects: 18
Study 10086330 — intervention group
Group type: COMPARATOR
Intervention: Daily doses of 3 or 6 10(6) IL‐2 units/m2
Number of subjects: 18
Study 10086330 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 patients)
Number of subjects: 18
Study 7586463 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG within 48 hours after Q-wave infarction
Number of subjects: 371
Study 7586463 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG between 3 and 5 days after Q-wave infarction
Number of subjects: 371
Study 7586463 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG after 5 days after Q-wave infarction
Number of subjects: 371
Study 7586463 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG for non-Q-wave infarction
Number of subjects: 371
Study 7586463 — intervention group
Group type: COMPARATOR
Intervention: Control group (CABG for angina without infarction)
Number of subjects: 371
Study 7586463 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG after Q-wave infarction
Number of subjects: 371
Study 2265095 — intervention group
Group type: EXPERIMENTAL
Intervention: MeZinc (adhesive zinc oxide tape)
Number of subjects: 44
Study 2265095 — intervention group
Group type: COMPARATOR
Intervention: DuoDerm (adhesive occlusive hydrocolloid dressing)
Number of subjects: 44
Study 7139063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release formulation
Number of subjects: 0
Study 7139063 — intervention group
Group type: COMPARATOR
Intervention: Three 25 mg conventional doses given at 4‐h intervals (control)
Number of subjects: 0
Study 7139063 — intervention group
Group type: COMPARATOR
Intervention: Single 75 mg dose of conventional capsules (control)
Number of subjects: 0
Study 7139063 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dose (control)
Number of subjects: 0
Study 31952174 — intervention group
Group type: EXPERIMENTAL
Intervention: CrM-HMB (0.04 g/kg/day of CrM plus 3 g/day of HMB)
Number of subjects: 28
Study 30720346 — intervention group
Group type: EXPERIMENTAL
Intervention: ER/DS mask
Number of subjects: 19
Study 30720346 — intervention group
Group type: COMPARATOR
Intervention: Sham mask
Number of subjects: 19
Study 28601622 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute rope skipping activity with intervals and rests
Number of subjects: 731
Study 28601622 — intervention group
Group type: COMPARATOR
Intervention: Usual practices (Control)
Number of subjects: 731
Study 25898692 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy patch test (APT)
Number of subjects: 521
Study 25898692 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick testing (SPT)
Number of subjects: 521
Study 25898692 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro IgE measurement (CAP/RAST)
Number of subjects: 521
Study 25898692 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 521
Study 23670958 — intervention group
Group type: EXPERIMENTAL
Intervention: HE3286 (17α‐ethynylandrost‐5‐ene‐3β,7β,17β‐triol)
Number of subjects: 0
Study 23670958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23670958 — intervention group
Group type: EXPERIMENTAL
Intervention: HE3286
Number of subjects: 0
Study 21971474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training exercises for verbal memory improvement over a two-month period
Number of subjects: 12
Study 21971474 — intervention group
Group type: COMPARATOR
Intervention: Active control group performing other computer activities
Number of subjects: 12
Study 20084326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg patch)
Number of subjects: 50
Study 20084326 — intervention group
Group type: COMPARATOR
Intervention: Oral nifedipine (20 mg)
Number of subjects: 50
Study 17027104 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-releasing aspirin (NORA)
Number of subjects: 40
Study 17027104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diabetes)
Number of subjects: 40
Study 15478208 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil spray or gargle formulation
Number of subjects: 0
Study 11682284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronobiological interventions related to reproductive hormones (specific details not provided)
Number of subjects: 0
Study 10211010 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg kg‐1 as drops
Number of subjects: 44
Study 10211010 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.1 mg kg‐1 from an intranasal spray device
Number of subjects: 44
Study 10211010 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (both methods)
Number of subjects: 44
Study 10211010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (both methods)
Number of subjects: 44
Study 8165823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (F) administered intravenously (i.v.)
Number of subjects: 0
Study 8165823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (F) administered orally (p.o.)
Number of subjects: 0
Study 2893084 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA‐125 measurement
Number of subjects: 1010
Study 2893084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal examination
Number of subjects: 1010
Study 2893084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serum CA‐125 measurement with ultrasound
Number of subjects: 1010
Study 2893084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vaginal examination with ultrasound
Number of subjects: 1010
Study 2893084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serum CA‐125 measurement with vaginal examination
Number of subjects: 1010
Study 2893084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three tests (serum CA‐125 measurement, vaginal examination, ultrasound)
Number of subjects: 1010
Study 29501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 428
Study 29501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of functioning
Number of subjects: 428
Study 29501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 428
Study 29501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 428
Study 29501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship relations
Number of subjects: 428
Study 29501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication (olanzapine, clozapine, quetiapine)
Number of subjects: 428
Study 29501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic symptoms and duration of illness
Number of subjects: 428
Study 28463833 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/h clazosentan
Number of subjects: 181
Study 28463833 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/h clazosentan
Number of subjects: 181
Study 28463833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 25030039 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ALL
Number of subjects: 109
Study 25030039 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps weakness
Number of subjects: 109
Study 24280476 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic interventions under DRG conditions
Number of subjects: 4598
Study 24280476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DRG system)
Number of subjects: 4598
Study 21477171 — intervention group
Group type: COMPARATOR
Intervention: Exclusive caesarean section deliveries
Number of subjects: 3763
Study 21477171 — intervention group
Group type: COMPARATOR
Intervention: Combination of caesarean and spontaneous vaginal births
Number of subjects: 3763
Study 21477171 — intervention group
Group type: COMPARATOR
Intervention: Exclusive caesarean births
Number of subjects: 3763
Study 21477171 — intervention group
Group type: COMPARATOR
Intervention: Mixed caesarean and spontaneous vaginal births
Number of subjects: 3763
Study 18194525 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention (stepwise approach to return-to-work plan)
Number of subjects: 0
Study 18194525 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 15814479 — intervention group
Group type: EXPERIMENTAL
Intervention: GAI‐Estimate (GAI‐E) algorithms developed from the Development group (n=1,200)
Number of subjects: 2401
Study 15814479 — intervention group
Group type: EXPERIMENTAL
Intervention: GAI‐Estimate (GAI‐E) algorithms
Number of subjects: 2401
Study 15814479 — intervention group
Group type: COMPARATOR
Intervention: Validation group (n=1,201)
Number of subjects: 2401
Study 12433231 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (three 100 mg doses per day)
Number of subjects: 10
Study 12433231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12433231 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 10
Study 10497376 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive load detection in asthmatic children
Number of subjects: 103
Study 10497376 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical approaches in pediatric asthma
Number of subjects: 103
Study 8722435 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0
Study 8722435 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 8722435 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin and Enalapril
Number of subjects: 0
Study 1888693 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg once daily for 3 weeks
Number of subjects: 12
Study 6353270 — intervention group
Group type: EXPERIMENTAL
Intervention: Butriptyline
Number of subjects: 77
Study 6353270 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 77
Study 31043095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab autoinjector (AI)
Number of subjects: 215
Study 31043095 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab prefilled syringe (PFS)
Number of subjects: 215
Study 29228848 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative group (closed reduction and fixation with a percutaneous screw)
Number of subjects: 46
Study 29228848 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group (immobilization with plaster)
Number of subjects: 46
Study 26666771 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet about Vietnam's government‐run scheme and the benefits of health insurance
Number of subjects: 3000
Study 26666771 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher entitling eligible household members to 25% off their annual premium
Number of subjects: 3000
Study 26666771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both information leaflet and voucher
Number of subjects: 3000
Study 26666771 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidy-only intervention
Number of subjects: 3000
Study 26666771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (information leaflet + voucher)
Number of subjects: 3000
Study 26666771 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3000
Study 24035143 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐CHESS smartphone application
Number of subjects: 152
Study 22151478 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent recovery housing with reinforcement-based treatment (RH + RBT)
Number of subjects: 243
Study 22151478 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery housing alone (RH)
Number of subjects: 243
Study 22151478 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 243
Study 20854045 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Psychological Intervention (MPI)
Number of subjects: 187
Study 20854045 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 187
Study 16389162 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin
Number of subjects: 57
Study 16389162 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin + Pio (30 mg daily)
Number of subjects: 57
Study 16389162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea and Metformin (SU+M)
Number of subjects: 57
Study 14607169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical patients
Number of subjects: 0
Study 14607169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical patients
Number of subjects: 0
Study 14607169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 0
Study 14607169 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 11077389 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (28 capsules, 500 mg each, taken every 6 hours for 7 days)
Number of subjects: 40
Study 11077389 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (exact details not specified)
Number of subjects: 40
Study 8724325 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with lithium or carbamazepine
Number of subjects: 0
Study 8724325 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics, particularly clozapine
Number of subjects: 0
Study 8724325 — intervention group
Group type: COMPARATOR
Intervention: High doses of neuroleptics
Number of subjects: 0
Study 8724325 — intervention group
Group type: EXPERIMENTAL
Intervention: New atypical neuroleptics
Number of subjects: 0
Study 1580837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 304
Study 3899571 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg diltiazem
Number of subjects: 15
Study 3899571 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 15
Study 3899571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31013372 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT) for peanut allergy over 2 years
Number of subjects: 57
Study 31013372 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 57
Study 31013372 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT) for peanut allergy
Number of subjects: 57
Study 30209017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ambrisentan 10 mg plus tadalafil 40 mg)
Number of subjects: 605
Study 30209017 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (either ambrisentan or tadalafil plus placebo)
Number of subjects: 605
Study 27387743 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC positivity (detected using MICC)
Number of subjects: 1221
Study 27387743 — intervention group
Group type: COMPARATOR
Intervention: CTC negativity (not detected using MICC)
Number of subjects: 1221
Study 24622668 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 788
Study 24622668 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 788
Study 22525081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine formulation (31.5 mg) administered intranasally
Number of subjects: 13
Study 22525081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inhalation (gentle or vigorous sniff)
Number of subjects: 13
Study 22525081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray pump delivery device
Number of subjects: 13
Study 22525081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cavity clearance
Number of subjects: 13
Study 22525081 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle inhalation
Number of subjects: 13
Study 19895623 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 220
Study 17931895 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCA prosthesis (fixation with wire cables)
Number of subjects: 35
Study 17931895 — intervention group
Group type: COMPARATOR
Intervention: HAS prosthesis (fixation with transosseous braided sutures)
Number of subjects: 35
Study 16000624 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta‐adrenoceptor antagonist)
Number of subjects: 78
Study 16000624 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (selective norepinephrine reuptake inhibitor)
Number of subjects: 78
Study 16000624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 11916759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (1500 retinol equivalents or 5000 IU) and Zinc (15 mg) supplementation daily for 6 months
Number of subjects: 80
Study 11916759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10401802 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH intervention
Number of subjects: 3714
Study 10401802 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3714
Study 7564449 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm antegrade delivery of cardioplegic solution (N = 25)
Number of subjects: 75
Study 7564449 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm retrograde delivery of cardioplegic solution (N = 25)
Number of subjects: 75
Study 7564449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of warm antegrade and retrograde delivery of cardioplegic solution (N = 25)
Number of subjects: 75
Study 1675049 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% flurbiprofen
Number of subjects: 18
Study 1675049 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 18
Study 1675049 — intervention group
Group type: COMPARATOR
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 18
Study 1675049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 18
Study 7023308 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin treatment for 8 weeks
Number of subjects: 15
Study 7023308 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study 31874733 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based injury prevention program (IPP) performed for eight weeks at training
Number of subjects: 65